EP3390634A4 - Compositions et méthodes pour le traitement de maladies oculaires - Google Patents

Compositions et méthodes pour le traitement de maladies oculaires Download PDF

Info

Publication number
EP3390634A4
EP3390634A4 EP16876610.3A EP16876610A EP3390634A4 EP 3390634 A4 EP3390634 A4 EP 3390634A4 EP 16876610 A EP16876610 A EP 16876610A EP 3390634 A4 EP3390634 A4 EP 3390634A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
eye diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16876610.3A
Other languages
German (de)
English (en)
Other versions
EP3390634A1 (fr
Inventor
Isabel AZNAREZ
Huw M. Nash
Samuel W. HALL
Sassan Azarian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Stoke Therapeutics Inc
Original Assignee
Cold Spring Harbor Laboratory
Stoke Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory, Stoke Therapeutics Inc filed Critical Cold Spring Harbor Laboratory
Publication of EP3390634A1 publication Critical patent/EP3390634A1/fr
Publication of EP3390634A4 publication Critical patent/EP3390634A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
EP16876610.3A 2015-12-14 2016-12-14 Compositions et méthodes pour le traitement de maladies oculaires Pending EP3390634A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267259P 2015-12-14 2015-12-14
US201662318958P 2016-04-06 2016-04-06
PCT/US2016/066691 WO2017106370A1 (fr) 2015-12-14 2016-12-14 Compositions et méthodes pour le traitement de maladies oculaires

Publications (2)

Publication Number Publication Date
EP3390634A1 EP3390634A1 (fr) 2018-10-24
EP3390634A4 true EP3390634A4 (fr) 2019-08-14

Family

ID=59057531

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16876610.3A Pending EP3390634A4 (fr) 2015-12-14 2016-12-14 Compositions et méthodes pour le traitement de maladies oculaires

Country Status (4)

Country Link
EP (1) EP3390634A4 (fr)
JP (2) JP7036723B2 (fr)
CA (1) CA3005128A1 (fr)
WO (1) WO2017106370A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
KR102620328B1 (ko) 2014-10-03 2024-01-02 콜드스프링하버러보러토리 핵 유전자 산출량의 표적화 증강
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (fr) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Oligomères antisens destinés au traitement du retard mental dominant autosomique 5 et du syndrome de dravet
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
MX2019012169A (es) 2017-04-11 2019-12-11 Regeneron Pharma Ensayos para evaluar la actividad de moduladores de miembros de la familia de hidroxiesteroide (17-beta) deshidrogenasa (hsd17b).
GB201706009D0 (en) * 2017-04-13 2017-05-31 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of stargardt disease
SG10202108375XA (en) 2017-08-25 2021-09-29 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
KR20200062314A (ko) 2017-10-11 2020-06-03 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
GB2584204B (en) * 2017-10-23 2023-06-28 Stoke Therapeutics Inc Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
RU177889U1 (ru) * 2017-11-30 2018-03-15 Общество с ограниченной ответственностью "Вертикаль-М" (ООО "Вертикаль-М") Дренаж для хирургического лечения глаукомы
EP3781213A4 (fr) * 2018-04-17 2022-10-19 The Trustees of the University of Pennsylvania Molécules de trans-épissage
JP2021526823A (ja) * 2018-06-14 2021-10-11 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｓｔｍｎ２発現を増加させるための化合物及び方法
CR20210058A (es) * 2018-07-03 2021-03-22 Hoffmann La Roche Oligonucleótidos para modular la expresión de tau
WO2020154686A1 (fr) * 2019-01-25 2020-07-30 Nayan Therapeutics, Inc. Oligonucléotides réducteurs d'expression de nr2e3, compositions les contenant, et leurs procédés d'utilisation
MX2022002198A (es) * 2019-08-19 2022-05-24 Stoke Therapeutics Inc Composiciones y métodos para modular el empalme y la expresión de proteínas.
US20230287410A1 (en) 2020-05-11 2023-09-14 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
WO2023104693A1 (fr) * 2021-12-07 2023-06-15 F. Hoffmann-La Roche Ag Oligonucléotides antisens ciblant actl6b
WO2023160454A1 (fr) * 2022-02-25 2023-08-31 北京中因科技有限公司 Combinaison de cassette d'expression et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035091A1 (fr) * 2013-09-04 2015-03-12 Cold Spring Harbor Laboratory Réduction de dégradation d'arnm à médiation non-sens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630241B1 (fr) * 2010-10-22 2018-10-17 CuRNA, Inc. Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua
EP3778618A1 (fr) * 2013-02-04 2021-02-17 Ionis Pharmaceuticals, Inc. Composés antisens sélectifs et leurs utilisations
GB201410693D0 (en) * 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
KR102620328B1 (ko) * 2014-10-03 2024-01-02 콜드스프링하버러보러토리 핵 유전자 산출량의 표적화 증강

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035091A1 (fr) * 2013-09-04 2015-03-12 Cold Spring Harbor Laboratory Réduction de dégradation d'arnm à médiation non-sens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JANA KRALOVICOVA ET AL: "Optimal antisense target reducing INS intron 1 retention is adjacent to a parallel G quadruplex", NUCLEIC ACIDS RESEARCH, vol. 42, no. 12, 8 July 2014 (2014-07-08), pages 8161 - 8173, XP055211568, ISSN: 0305-1048, DOI: 10.1093/nar/gku507 *
TAKEMASA SAKAGUCHI ET AL: "Optineurin with amyotrophic lateral sclerosis-related mutations abrogates inhibition of interferon regulatory factor-3 activation", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 505, no. 3, 15 October 2011 (2011-10-15), pages 279 - 281, XP028114208, ISSN: 0304-3940, [retrieved on 20111021], DOI: 10.1016/J.NEULET.2011.10.040 *

Also Published As

Publication number Publication date
WO2017106370A1 (fr) 2017-06-22
JP7036723B2 (ja) 2022-03-15
JP2019500348A (ja) 2019-01-10
CA3005128A1 (fr) 2017-06-22
EP3390634A1 (fr) 2018-10-24
JP2022046724A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3261440A4 (fr) Méthodes et compositions de traitement de maladies oculaires génétiques
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3224278A4 (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
EP3389672A4 (fr) Compositions et procédés de traitement de maladies hépatiques
EP3347368A4 (fr) Composés et formulations pour traiter les maladies ophthalmiques
IL246791A0 (en) Compositions and methods for treating eye diseases
EP3185876A4 (fr) Compositions et procédés de traitement de troubles neurologiques
EP3390666A4 (fr) Compositions et méthodes de traitement de maladies rénales
EP3240612A4 (fr) Procédés de traitement de maladies rétiniennes
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3265096A4 (fr) Compositions ophtalmiques et leurs procédés d'utilisation
EP3139928A4 (fr) Compositions d'anordrine et méthodes de traitement de maladies
EP3131556A4 (fr) Méthodes et compositions pour le traitement de maladies liées à la bpco
EP3110446A4 (fr) Procédés et compositions pour le traitement de maladies associées à siglec-8
EP3515444A4 (fr) Composition destinée au traitement de maladies oculaires, et méthodes d'utilisation et procédés de fabrication
EP3086809A4 (fr) Compositions et procédés de traitement de troubles oculaires
EP3240577A4 (fr) Procédés et compositions de traitement de maladies cérébrales
EP3253211A4 (fr) Compositions et méthodes pour traiter l'oedème
EP3340974A4 (fr) Méthodes de traitement de maladies
EP3484526A4 (fr) Compositions et méthodes destinées au traitement de maladies cardiaques
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3713553A4 (fr) Compositions et méthodes de traitement des maladies oculaires

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AZNAREZ, ISABEL

Inventor name: NASH, HUW M.

Inventor name: HALL, SAMUEL W.

Inventor name: AZARIAN, SASSAN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190711

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101ALI20190705BHEP

Ipc: C12N 15/113 20100101AFI20190705BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262958

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRAINER,ADRIAN

Inventor name: AZNAREZ, ISABEL

Inventor name: AZARIAN, SASSAN

Inventor name: NASH, HUW M.

Inventor name: HALL, SAMUEL W.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230922